thalidomide has been researched along with Leiomyosarcoma, Epithelioid in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy and adverse events (AEs) of thalidomide in previously treated, measurable, persistent or recurrent leiomyosarcoma (LMS) of the uterus, and to explore associations between angiogenic markers and treatment or clinical outcome." | 9.12 | A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study. ( Benbrook, D; Darcy, KM; McMeekin, DS; Sill, MW; Stearns-Kurosawa, DJ; Waggoner, S; Webster, K, 2007) |
| "To evaluate the efficacy and adverse events (AEs) of thalidomide in previously treated, measurable, persistent or recurrent leiomyosarcoma (LMS) of the uterus, and to explore associations between angiogenic markers and treatment or clinical outcome." | 5.12 | A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study. ( Benbrook, D; Darcy, KM; McMeekin, DS; Sill, MW; Stearns-Kurosawa, DJ; Waggoner, S; Webster, K, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| McMeekin, DS | 1 |
| Sill, MW | 1 |
| Darcy, KM | 1 |
| Stearns-Kurosawa, DJ | 1 |
| Webster, K | 1 |
| Waggoner, S | 1 |
| Benbrook, D | 1 |
| Kurstin, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT02748772] | Phase 3 | 148 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for thalidomide and Leiomyosarcoma, Epithelioid
| Article | Year |
|---|---|
A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antigens, CD; Biomarkers, Tumor; Dose-Response Relationship, D | 2007 |
1 other study available for thalidomide and Leiomyosarcoma, Epithelioid
| Article | Year |
|---|---|
Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease.
Topics: Abdominal Neoplasms; Aged; Angiogenesis Inhibitors; Humans; Leiomyosarcoma; Male; Telangiectasia, He | 2002 |